Longeveron shares surge 10.92% premarket on FDA designations and positive stem cell therapy trial results.

Longeveron Inc. surged 10.92% in premarket trading following positive developments in its stem cell therapy pipeline. The stock’s rise was driven by news that the company’s laromestrocel therapy demonstrated statistically meaningful improvements in physical function during a Phase 2b trial, alongside an FDA designation update. These results, combined with a $15M funding raise to support further development, bolstered investor confidence in the therapy’s potential for frailty treatment. While the Q4 2025 earnings guidance remains weak, the immediate catalyst for the premarket rally was the clinical progress and regulatory momentum, which overshadowed near-term financial concerns.